Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) EBT Margin: 2014-2025

Historic EBT Margin for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to -209.94%.

  • ImmunityBio's EBT Margin rose 119445.00% to -209.94% in Q3 2025 from the same period last year, while for Sep 2025 it was -422.38%, marking a year-over-year increase of 759617.00%. This contributed to the annual value of -2,805.32% for FY2024, which is 9106799.00% up from last year.
  • Per ImmunityBio's latest filing, its EBT Margin stood at -209.94% for Q3 2025, which was up 39.90% from -349.31% recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's EBT Margin ranged from a high of -209.94% in Q3 2025 and a low of -735,700.00% during Q1 2022.
  • For the 3-year period, ImmunityBio's EBT Margin averaged around -91,435.56%, with its median value being -12,854.25% (2024).
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by 67,780,432bps in 2022, then soared by 70,331,583bps in 2023.
  • Over the past 5 years, ImmunityBio's EBT Margin (Quarterly) stood at -23,474.87% in 2021, then crashed by 12,487,033bps to -148,345.21% in 2022, then plummeted by 1,960,731bps to -167,952.52% in 2023, then skyrocketed by 16,716,890bps to -783.62% in 2024, then soared by 119,445bps to -209.94% in 2025.
  • Its EBT Margin stands at -209.94% for Q3 2025, versus -349.31% for Q2 2025 and -786.46% for Q1 2025.